Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clarification on dissolving solutions

This article was originally published in The Tan Sheet

Executive Summary

FDA clarifies that 0.13 percent to 0.5 percent aluminum acetate solutions, produced by dissolving aluminum sulfate tetradecahydrate and calcium acetate monohydrate in powder or tablet form, are generally recognized as safe and effective and not misbranded as astringent drug products. In a March 6 1final rule amending the final monograph for OTC skin protectant astringents, the agency also describes how manufacturers should relabel products. The rule grants the request from a 1995 citizen petition to revise FDA's 1993 monograph by including aluminum sulfate-calcium acetate combinations in powders and tablets to prepare an aluminum acetate solution. Labels must state the amount of each active ingredient and that those amounts, when dissolved in the indicated amount of water, must produce a 0.13 to 0.5 percent aluminum acetate solution. The compliance deadline is August 2010, FDA says

You may also be interested in...

More Top-Level Pharma Changes In India, Cipla Gets CSO

Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.

India Acts To Limit Supply Disruption From Coronavirus

Indian pharmaceutical companies will soon be asked to seek a no objection certificate for the export of 12 APIs and their formulations, as the country deals with Chinese raw material supply disruptions on the back of the coronavirus crisis. However, the move is not expected to impact the export quantum for now.

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts